Skip to content

Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats

Effect of Lactoferrin Administration on Rhabdomyolysis-induced Heart and Kidney Injury in Rats

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06491394
Enrollment
24
Registered
2024-07-09
Start date
2024-11-01
Completion date
2025-04-01
Last updated
2025-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhabdomyolysis

Brief summary

This study focuses on detecting the possible beneficial effect of Lactoferrin (Lf) administration on the kidney and the heart of glycerol-induced rhabdomyolysis (RM) in rats and its relation to ferroptosis and AMPK/Nrf2/ HO-1 signalling pathway. The main questions it aims to answer are: 1. Is Lf administration 30 min. before or after RM induction in rats beneficial to kidneys and heart? 2. When administered to glycerol-induced rats, does Lf act by upregulating the AMPK/Nrf2/ HO-1 signalling pathway and inhibiting ferroptosis?

Interventions

DRUGLactoferrin

an iron-binding protein

DIAGNOSTIC_TESTiron

Iron in kidney and heart tissues

DIAGNOSTIC_TESTMDA, TAC, and GSH

Oxidative stress levels in kidney and heart tissues

DIAGNOSTIC_TESTNrf2

Nrf2 expression in kidney and heart tissues

DIAGNOSTIC_TESTAMPK

AMPK levels in heart and kidney tissues

DIAGNOSTIC_TESTHO-1

HO-1 levels in kidney and heart tissues

GLY intramuscular injection for rhabdomyolysis induction

Sponsors

Aswan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
10 Weeks to 12 Weeks
Healthy volunteers
No

Inclusion criteria

* • Twenty-four healthy male Wistar Albino rats weighing from 250 to 300 g

Exclusion criteria

* No

Design outcomes

Primary

MeasureTime frameDescription
Nrf2 expression2 monthsNrf2 expression in heart and kidney tissues
AMPK levels2 monthsAMPK levels in kidney and heart tissue homogenate
HO-1 levels2 monthsHO-1 levels in kidney and heart tissue homogenate

Secondary

MeasureTime frameDescription
iron levels2 monthsIron levels in heart and kidney tissue homogenate
GSH levels2 monthsGSH levels in heart and kidney tissue homogenate
MDA levels2 monthsMDA levels in heart and kidney tissue homogenate
TAC levels2 monthsTAC levels in heart and kidney tissue homogenate

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026